Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (24)

2024

  1. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma

    Leukemia and Lymphoma, Vol. 65, Núm. 3, pp. 323-332

  2. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood

2023

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

  2. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

    Leukemia

  3. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    The Lancet, Vol. 401, Núm. 10373, pp. 269-280

  4. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  2. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 31, Núm. 9, pp. 1863-1866

  3. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

    Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843

  4. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639

  5. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Nature Medicine, Vol. 28, Núm. 2, pp. 325-332

2021

  1. Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients

    International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336

2016

  1. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

    Cancer, Vol. 122, Núm. 14, pp. 2178-2185

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial

    Haematologica, Vol. 100, Núm. 8, pp. 1096-1102

  2. Revised international staging system for multiple myeloma: A report from international myeloma working group

    Journal of Clinical Oncology, Vol. 33, Núm. 26, pp. 2863-2869

  3. Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement

    Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 657-664

2014

  1. New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)

    Leukemia, Vol. 28, Núm. 3, pp. 525-542

2013

  1. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm

    British Journal of Haematology, Vol. 161, Núm. 5, pp. 667-676

  2. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Leukemia, Vol. 27, Núm. 4, pp. 780-791